Raymedica is involved in the development of a nucleus replacement technology aimed at preserving the motion of the spine and is a pioneer in the field of Nucleus Arthroplasty™.

The availability of a wide range of technologically superior bone grafts provides surgeons with the flexibility to choose suitable grafts for specific needs, increasingly making allografts the procedure of choice.

Enhanced technological integration and ease-of-use will enable sophisticated manufacturers in the South African patient monitoring market to compete with cheaper, but comparatively less powerful, Chinese-made offerings. At the same time, efforts to significantly lower prices will also support uptake levels.